Search Results for "1"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for 1. Results 571 to 580 of 2440 total matches.
Sodium Zirconium Cyclosilicate (Lokelma) for Hyperkalemia
The Medical Letter on Drugs and Therapeutics • Dec 03, 2018 (Issue 1561)
polystyrene sulfonate and
patiromer (Veltassa)1 were approved earlier.
Pronunciation Key
Lokelma: low kel ...
The FDA has approved sodium zirconium cyclosilicate
(Lokelma – AstraZeneca), an oral potassium binder that
exchanges hydrogen and sodium for potassium in the
gastrointestinal (GI) lumen, for treatment of non-life-threatening
hyperkalemia in adults. Sodium zirconium
cyclosilicate (SZC) is the third drug to be approved
for this indication; sodium polystyrene sulfonate and
patiromer (Veltassa) were approved earlier.
Angiotensin II (Giapreza) for Septic Shock
The Medical Letter on Drugs and Therapeutics • Dec 03, 2018 (Issue 1561)
of norepinephrine,
a potent alpha1- and beta1-adrenergic agonist,
as the initial vasopressor of choice.1 ...
The FDA has approved (Giapreza) (La Jolla), an IV
formulation of synthetic angiotensin II, to increase
blood pressure in adults with septic or other vasodilatory
shock, such as anaphylactic or neurogenic
shock. Angiotensin is a naturally occurring peptide
hormone in the renin-angiotensin-aldosterone system
(RAAS). (Giapreza) is the first synthetic angiotensin II
product to become available in the US.
IV Aprepitant (Cinvanti) for Chemotherapy-Induced Nausea and Vomiting (online only)
The Medical Letter on Drugs and Therapeutics • Dec 03, 2018 (Issue 1561)
The FDA has approved Cinvanti (Heron), an IV
emulsion formulation of the substance P/neurokinin-1 ...
The FDA has approved Cinvanti (Heron), an IV
emulsion formulation of the substance P/neurokinin-1
(NK1) receptor antagonist aprepitant, for prevention
of acute and delayed chemotherapy-induced nausea
and vomiting (CINV) in adults. Aprepitant is also
available in oral capsule and suspension formulations
(Emend, and generics), and fosaprepitant, a prodrug of
aprepitant, is available in an IV formulation (Emend for
injection).
Juluca - A Two-Drug Complete Regimen for HIV (online only)
The Medical Letter on Drugs and Therapeutics • Dec 03, 2018 (Issue 1561)
-1 infection who do not have a history of
treatment failure or known substitutions associated ...
The FDA has approved Juluca (ViiV Healthcare/Janssen), a fixed-dose combination of the integrase
strand transfer inhibitor (INSTI) dolutegravir (Tivicay)
and the non-nucleoside reverse transcriptase
inhibitor (NNRTI) rilpivirine (Edurant), as a once-daily
complete regimen for treatment of adults
with HIV-1 infection who do not have a history of
treatment failure or known substitutions associated
with resistance to either drug and have been taking
a stable suppressive antiretroviral regimen for ≥6
months. Dolutegravir/rilpivirine is the first complete
regimen to be approved for...
Vaccines for Travelers
The Medical Letter on Drugs and Therapeutics • Nov 19, 2018 (Issue 1560)
immunization are discussed in a separate issue.1
TIMING OF VACCINE ADMINISTRATION
Multiple inactivated ...
Persons planning to travel outside the US should be
up to date on routine vaccines and, depending on their
destination, duration of travel, and planned activities,
may also receive certain travel-specific vaccines.
Tickborne encephalitis and dengue vaccines, which
are not available in the US, are reviewed in a separate
article available online. Detailed advice for travel to
specific destinations is available from the Centers for
Disease Control and Prevention (CDC) at www.cdc.gov/travel/destinations/list. Recommendations for
administration of vaccines as part of routine...
Expanded Table: Some Vaccines for Travelers (online only)
The Medical Letter on Drugs and Therapeutics • Nov 19, 2018 (Issue 1560)
with chloroquine
Hepatitis A (HepA)
Havrix (GSK)
Vaqta (Merck)
1 mL IM (1440 EL.U)
1 mL IM (50 units)
1-18 ...
View the Expanded Table: Some Vaccines for Travelers
Tickborne Encephalitis and Dengue Vaccines (online only)
The Medical Letter on Drugs and Therapeutics • Nov 19, 2018 (Issue 1560)
; 0 and 1-7 months for TBE-Moscow); a rapid
schedule of EnceVir (0 and 1-2 months) can be used ...
No vaccines against tickborne encephalitis (TBE) or
dengue are available in the US, but vaccines have been
licensed in some other countries.
Plazomicin (Zemdri) - A New Aminoglycoside Antibiotic
The Medical Letter on Drugs and Therapeutics • Nov 05, 2018 (Issue 1559)
are generally used short-term
because of their potential toxicity.
Table 1. Pharmacology and Dosage
Class ...
The FDA has approved the new aminoglycoside
antibiotic plazomicin (Zemdri – Achaogen) for IV
treatment of adults with complicated urinary tract
infections (cUTIs). Plazomicin is active against multi-drug-
resistant Enterobacteriaceae, including strains
resistant to other aminoglycosides.
Cannabidiol (Epidiolex) for Epilepsy
The Medical Letter on Drugs and Therapeutics • Nov 05, 2018 (Issue 1559)
, and a high
mortality rate.1 Off-label pharmacologic treatment of
Dravet syndrome has included valproate ...
The FDA has approved cannabidiol oral solution
(Epidiolex – Greenwich Biosciences) for treatment
of seizures associated with Dravet syndrome or
Lennox-Gastaut syndrome in patients ≥2 years old.
Cannabidiol (CBD) is a cannabinoid constituent of
the marijuana plant (Cannabis sativa). It is the first
natural marijuana product to be approved by the FDA
for any indication and the first drug to be approved in
the US for treatment of Dravet syndrome. Stiripentol
(Diacomit), which is not a marijuana product, was also
recently approved by the FDA for treatment of Dravet
syndrome in...
Fremanezumab (Ajovy) and Galcanezumab (Emgality) for Migraine Prevention
The Medical Letter on Drugs and Therapeutics • Nov 05, 2018 (Issue 1559)
-aooe (Aimovig), which targets the CGRP
receptor, was the first.1
Fremanezumab (Ajovy ...
The FDA has approved two subcutaneously
injected calcitonin gene-related peptide (CGRP)
antagonists, fremanezumab-vfrm (Ajovy – Teva) and
galcanezumab-gnlm (Emgality – Lilly), for migraine
prevention in adults. Fremanezumab and galcanezumab
are the second and third subcutaneously
injected monoclonal antibodies that target the CGRP
pathway to be approved by the FDA for this indication;
erenumab-aooe (Aimovig), which targets the CGRP
receptor, was the first.